Company: VLDXW
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001641172-25-022448
Chunk: 34

Company: Velo3D, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
”) and the related prospectus
supplement and accompanying base prospectus, and in connection therewith, the Company reserved 38,096 shares of common stock for issuance
under the ATM Sales Agreement. On January 31, 2024, the Company filed an amendment to the prospectus supplement increasing the aggregate
dollar amount of shares available to be sold from time to time pursuant to the ATM Sales Agreement to $75 million. During six months
ended June 30, 2025, the Company sold no shares pursuant to the ATM sales agreement.

In
April 2024, pursuant to the evergreen provisions of the Company’s 2021 Equity Incentive Plan (the “2021 EIP”), the
Company added an additional 24,612 shares of common stock for issuance under the 2021 EIP and 4,917 shares of common stock for issuance
under the 2021 ESPP.

The
shares available for future grant under the 2021 EIP are net of any un-exercised stock options (vested and unvested) and unvested restricted
stock units (“RSUs”) outstanding that may convert to common stock in the future upon exercise or vesting as of June 30,
2025 and December 31, 2024.

    18

Common
Stock Warrant Liabilities

In
connection with the BEPO Offering, the Company issued BEPO Warrants to purchase up to an aggregate of 65,307 shares of common stock.
The BEPO Warrants are immediately exercisable at an exercise price of $183.75 per share and will expire on the five year anniversary
of the date of issuance. In connection with the BEPO Placement Agency Agreement, we also issued BEPO Agent Warrants to purchase up to
3,266 shares of common stock. The BEPO Agent Warrants are exercisable at an exercise price of $202.125 per share and will expire on the
five year anniversary of the date of issuance.

In
connection with the Second Note Amendment, on April 1, 2024, the Company also entered into a letter agreement (the “Letter Agreement”)
with the Investors pursuant to which the Company issued to the Investors warrants (the “2024 Private Warrants”) to purchase
up to an aggregate of 41,808 shares of Common Stock. The 2024 Private Warrants became exercisable 45 days after the original issuance
date (the “Initial Exercise Date”), are exercisable at